<DOC>
	<DOCNO>NCT01850940</DOCNO>
	<brief_summary>This phase IV , open-label , prospective cohort study 7 days.The recommend start dose tolvaptan 15 mg daily orally . The dose may titrate next day 15 mg interval 60 mg daily accord serum sodium level response.Serum sodium level , change sodium level baseline , quality life ( EQ-5D-3L ) , change body weight , edema , renal function , mortality liver-related complication day 7 day 30 evaluate efficacy tolvaptan cirrhotic patient hyponatremia .</brief_summary>
	<brief_title>Efficacy Safety Tolvaptan Cirrhotic Patients With Hyponatremia</brief_title>
	<detailed_description>Tolvaptan effective treatment hyponatremia . However , cirrhotic patient underrepresented previous study . The pattern use efficacy tolvaptan real-life clinical practice currently unknown.The objective study evaluate efficacy tolvaptan cirrhotic patient hyponatremia . The secondary objective evaluate short- intermediate-term safety tolvaptan cirrhotic patients.This phase IV , open-label , prospective cohort study 7 day . Although mandatory , study subject encourage undergo follow-up assessment 1 month.Subjects evaluate designated time point initiation therapy . The primary efficacy endpoint proportion subject normal serum sodium level ( 135-145 mmol/l ) day 7 . The secondary efficacy endpoint serum sodium level , change sodium level baseline , quality life ( EQ-5D-3L ) , change body weight , edema , renal function , mortality liver-related complication day 7 day 30 .</detailed_description>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Inclusion criterion : 1 . Age le 18 year ; 2 . Confirmed cirrhosis histology radiological feature cirrhosis clinical feature portal hypertension ; 3 . Serum sodium level le 135 mmol/L ; 4 . Inpatients . Exclusion criterion : 1 . Clinical feature hypovolemia ; 2 . Systolic blood pressure le 90 mmHg ; 3 . Life expectancy le one month ; 4 . History variceal bleed last six month ; 5 . Hepatic encephalopathy peritonitis last two week ; 6 . Serum creatinine 3.5 mg/dl ; 7 . Severe cardiopulmonary disease ; 8 . Urinary tract obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Cirrhotic Patients</keyword>
	<keyword>Hyponatremia</keyword>
	<keyword>tolvaptan</keyword>
</DOC>